BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 11:42:00 AM | Browse: 950 | Download: 1610
 |
Received |
|
2015-05-26 09:00 |
 |
Peer-Review Started |
|
2015-05-28 14:20 |
 |
To Make the First Decision |
|
2015-06-18 15:13 |
 |
Return for Revision |
|
2015-06-25 15:31 |
 |
Revised |
|
2015-07-10 21:11 |
 |
Second Decision |
|
2015-08-20 16:22 |
 |
Accepted by Journal Editor-in-Chief |
|
2015-08-21 13:05 |
 |
Accepted by Executive Editor-in-Chief |
|
2015-08-31 15:52 |
 |
Articles in Press |
|
2015-08-31 15:52 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2015-10-10 20:17 |
 |
Publish the Manuscript Online |
|
2015-10-19 09:39 |
ISSN |
1948-5204 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Editorial |
Article Title |
Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?
|
Manuscript Source |
Invited Manuscript |
All Author List |
Dimitra Grapsa, Muhammad Wasif Saif and Konstantinos Syrigos |
Funding Agency and Grant Number |
|
Corresponding Author |
Konstantinos Syrigos, MD, PhD, Professor, Head, Oncology Unit, 3rd Department of Medicine, “Sotiria” General Hospital, Athens University School of Medicine, Mesogion 152, 11527 Athens,
Greece. knsyrigos@usa.net
|
Key Words |
Clinical; Cytotoxic chemotherapy; Pancreatic cancer; Preclinical; Targeted agents |
Core Tip |
Expansion of our knowledge regarding the Expansion of our knowledge regarding the molecular basis of pancreatic cancer has facilitated the development of a significant number of innovative targeted therapies for this lethal disease. Almost all these agents have, nevertheless, failed to produce statistically significant survival benefits when tested in clinical trial settings; therefore, successful clinical translation of preclinical advancements in pancreatic cancer research has yet to be materialized. Future treatment options might include multi-targeted and individualized molecular therapies, ideally guided by patient-specific genomic data, in combination with conventional cytotoxic or other regimens.
molecular basis of pancreatic cancer has facilitated the development of a significant number of innovative targeted therapies for this lethal disease. Almost all these agents have, nevertheless, failed to produce statistically significant survival benefits when tested in clinical trial settings; therefore, successful clinical translation of preclinical advancements in pancreatic cancer research has yet to be materialized. Future treatment options might include multi-targeted and individualized molecular therapies, ideally guided by patient-specific genomic data, in combination with conventional cytotoxic or other regimens. |
Publish Date |
2015-10-19 09:39 |
Citation |
Grapsa D, Saif MW, Syrigos K. Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go? World J Gastrointest Oncol 2015; 7(10): 172-177 |
URL |
http://www.wjgnet.com/1948-5204/full/v7/i10/172.htm |
DOI |
http://dx.doi.org/10.4251/wjgo.v7.i10.172 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345